Moreover, our previous study revealed that endostatin 33 peptide is a disintegrin α6β1 agent that exerts antitumor activity by inhibiting the PI3K-Akt signaling pathway in prostate cancer [24]. Here, AKT1 is linked to prostate carcinoma.